blinatumomab sold brand name blincyto biopharmaceutical medication used secondline treatment philadelphia chromosomenegative relapsed refractory acute lymphoblastic leukemia belongs class constructed monoclonal antibodies bispecific tcell engagers bites exert action selectively direct human immune system act tumor cells blinatumomab specifically targets antigen present b december approved us food drug administration accelerated approval program marketing authorization depended outcome clinical trials ongoing time blinatumomab given continuous iv infusion consecutive days per dose depends patients actual body weight patients weighing kg receive fixed doses patients weighing less kg receive doses based estimated body surface blinatumomab originally approved treat philadelphia chromosomenegative relapsed refractory bcell precursor acute lymphoblastic leukemia adults approved us food drug administration fda bcell precursor acute lymphoblastic leukemia first second complete remission minimal residual disease greater equal well relapsed refractory bcell precursor blinatumomab bispecific tcell engager enables patients cells recognize malignant b cells molecule blinatumomab combines two binding sites site cells site target b cells part cell receptor drug works linking two cell types activating cell exert cytotoxic activity target expressed pediatric adult patients making blinatumomab potential therapeutic option pediatric adult drug originally known developed germanamerican company micromet inc cooperation lonza micromet purchased amgen furthered drugs clinical trials july fda granted breakthrough therapy status blinatumomab treatment acute lymphoblastic leukemia october amgens biologics license application blinatumomab granted priority review designation fda thus establishing deadline may completion fda review december drug approved use united states treat philadelphia chromosomenegative relapsed refractory acute lymphoblastic leukemia fdas accelerated approval program marketing authorization depended outcome clinical trials ongoing time blinatumomab approved amgen announced price drug would per year made expensive cancer drug market mercks pembrolizumab priced per year launched september time initial approval patients us indication peter bach director center health policy outcomes memorial sloankettering cancer center calculated according valuebased pricing assuming value year life toxicity discount market price blinatumomab month compared market price month representative amgen said price blincyto reflects significant clinical economic humanistic value product patients healthcare system price also reflects complexity developing manufacturing reliably supplying innovative biologic httpsenwikipediaorgwikiblinatumomab